2023-06-15T17:27:43Z
2023-06-15T17:27:43Z
2023-04-13
2023-06-15T17:27:43Z
Over 750 million cases of COVID-19, caused by the Severe Acute Respiratory Syndrome Corona-Virus 2 (SARS-CoV-2), have been reported since the onset of the global outbreak. The need for effective treatments has spurred intensive research for therapeutic agents based on pharmaceutical repositioning or natural products. In light of prior studies asserting the bioactivity of natural compounds of the autochthonous Peruvian flora, the present study focuses on the identification SARS-CoV-2 Mpro main protease dimer inhibitors. To this end, a target-based virtual screening was performed over a representative set of Peruvian flora-derived natural compounds. The best poses obtained from the ensemble molecular docking process were selected. These structures were subjected to extensive molecular dynamics steps for the computation of binding free energies along the trajectory and evaluation of the stability of the complexes. The compounds exhibiting the best free energy behaviors were selected for in vitro testing, confirming the inhibitory activity of Hyperoside against Mpro, with a Ki value lower than 20 µM, presumably through allosteric modulation
Article
Published version
English
SARS-CoV-2; Dinàmica molecular; Disseny de medicaments; SARS-CoV-2; Molecular dynamics; Drug design
MDPI
Reproducció del document publicat a: https://doi.org/10.3390/ph16040585
Pharmaceuticals, 2023, vol. 16, num. 4, p. 1-20
https://doi.org/10.3390/ph16040585
cc-by (c) Peralta-Moreno, Maria Núria et al., 2023
https://creativecommons.org/licenses/by/4.0/